218 related articles for article (PubMed ID: 8126248)
1. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
Watson A
J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
[TBL] [Abstract][Full Text] [Related]
2. Current perspectives: iron management during therapy with recombinant human erythropoietin.
York S
ANNA J; 1993 Dec; 20(6):645-50; quiz 651-2. PubMed ID: 8267408
[TBL] [Abstract][Full Text] [Related]
3. Anemia of renal failure. Use of erythropoietin.
Humphries JE
Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
[TBL] [Abstract][Full Text] [Related]
4. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
Glaspy J; Cavill I
Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
Eschbach JW; Abdulhadi MH; Browne JK; Delano BG; Downing MR; Egrie JC; Evans RW; Friedman EA; Graber SE; Haley NR
Ann Intern Med; 1989 Dec; 111(12):992-1000. PubMed ID: 2688507
[TBL] [Abstract][Full Text] [Related]
6. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy.
Goodnough LT
Nephrol Dial Transplant; 2002; 17 Suppl 5():14-8. PubMed ID: 12091601
[TBL] [Abstract][Full Text] [Related]
7. Iron deficiency in patients with renal failure.
Nissenson AR; Strobos J
Kidney Int Suppl; 1999 Mar; 69():S18-21. PubMed ID: 10084282
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
Tarng DC; Huang TP; Chen TW; Yang WC
Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
[TBL] [Abstract][Full Text] [Related]
9. rHuEpo before dialysis and in dialysed patients.
López-Gómez JM; Jofre R; Moreno F; Verde E; Valderràbano F
Nephrol Dial Transplant; 1995; 10 Suppl 6():31-5. PubMed ID: 8524491
[No Abstract] [Full Text] [Related]
10. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
11. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
[TBL] [Abstract][Full Text] [Related]
12. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
Abraham PA
Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
[TBL] [Abstract][Full Text] [Related]
13. Management of renal anemia.
Peco-Antic A
Turk J Pediatr; 2005; 47 Suppl():19-27. PubMed ID: 15884663
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin therapy in children on dialysis.
Jabs K; Harmon WE
Adv Ren Replace Ther; 1996 Jan; 3(1):24-36. PubMed ID: 8620365
[TBL] [Abstract][Full Text] [Related]
15. [Iron stores in patients with chronic kidney failure treated with recombinant human erythropoietin].
Cermák J; Gregora E; Lachmanová J; Brabec V
Vnitr Lek; 1994 Mar; 40(3):174-8. PubMed ID: 8184571
[TBL] [Abstract][Full Text] [Related]
16. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
Alexander SR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
[TBL] [Abstract][Full Text] [Related]
17. Nutritional implications of recombinant human erythropoietin therapy in renal disease.
Sanders HN; Rabb HA; Bittle P; Ramirez G
J Am Diet Assoc; 1994 Sep; 94(9):1023-9. PubMed ID: 8071484
[TBL] [Abstract][Full Text] [Related]
18. Novel aspects of erythropoietin response in renal failure patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 2001; 16 Suppl 5():40-4. PubMed ID: 11509683
[TBL] [Abstract][Full Text] [Related]
19. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration.
Herrera J; Nava M; Romero F; Rodríguez-Iturbe B
Am J Kidney Dis; 2001 Apr; 37(4):750-7. PubMed ID: 11273875
[TBL] [Abstract][Full Text] [Related]
20. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
